These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 36629124)

  • 1. An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer.
    Cai D; Wang W; Zhong ME; Fan D; Liu X; Li CH; Huang ZP; Zhu Q; Lv MY; Hu C; Duan X; Wu XJ; Gao F
    Cancer Med; 2023 Apr; 12(7):8924-8936. PubMed ID: 36629124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer.
    Matsuyama T; Kandimalla R; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kinugasa Y; Hansen TF; Fakih M; Uetake H; Győrffy B; Goel A
    Int J Cancer; 2020 Dec; 147(11):3250-3261. PubMed ID: 32657428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer-associated fibroblasts impact the clinical outcome and treatment response in colorectal cancer via immune system modulation: a comprehensive genome-wide analysis.
    Chen YF; Yu ZL; Lv MY; Cai ZR; Zou YF; Lan P; Wu XJ; Gao F
    Mol Med; 2021 Oct; 27(1):139. PubMed ID: 34717544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer.
    Matsuyama T; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kawano T; Uetake H; Goel A
    Mol Cancer; 2019 Feb; 18(1):19. PubMed ID: 30717807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of an EMT-related Gene Signature Predicting Recurrence in Stage II/III Colorectal Cancer: A Retrospective Study in 1780 Patients.
    Ren H; Bösch F; Pretzsch E; Jacob S; Westphalen CB; Walter Holch J; Werner J; Angele MK
    Ann Surg; 2022 Nov; 276(5):897-904. PubMed ID: 35880752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Individualized EMT-Related Gene Signature to Predict Recurrence-Free Survival in Stage II/III Colorectal Cancer Patients.
    Zhang W; Zhang X; Zhao D; Hu M; Ge X; Xia L
    Dig Dis Sci; 2022 Nov; 67(11):5116-5126. PubMed ID: 35094253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel tumor-based epithelial-to-mesenchymal transition score that associates with prognosis and metastasis in patients with Stage II/III colorectal cancer.
    Roseweir AK; Kong CY; Park JH; Bennett L; Powell AGMT; Quinn J; van Wyk HC; Horgan PG; McMillan DC; Edwards J; Roxburgh CS
    Int J Cancer; 2019 Jan; 144(1):150-159. PubMed ID: 29992570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel prognostic signature correlated with epithelial-mesenchymal transition, N6-methyladenosine modification, and immune infiltration in colorectal cancer.
    Qu X; Tan H; Mao J; Yang M; Xu J; Yan X; Wu W
    Cancer Med; 2023 Mar; 12(5):5926-5938. PubMed ID: 36281556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of prognostic immune-related gene signature associated with tumor microenvironment of colorectal cancer.
    Wang Y; Li W; Jin X; Jiang X; Guo S; Xu F; Su X; Wang G; Zhao Z; Gu X
    BMC Cancer; 2021 Aug; 21(1):905. PubMed ID: 34364366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel TGF-β-Related Signature for Predicting Prognosis, Tumor Microenvironment, and Therapeutic Response in Colorectal Cancer.
    Tao B; Yi C; Ma Y; Li Y; Zhang B; Geng Y; Chen Z; Ma X; Chen J
    Biochem Genet; 2024 Aug; 62(4):2999-3029. PubMed ID: 38062276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomics and prognosis analysis of epithelial-mesenchymal transition in colorectal cancer patients.
    Zhang Z; Zheng S; Lin Y; Sun J; Ding N; Chen J; Zhong J; Shi L; Xue M
    BMC Cancer; 2020 Nov; 20(1):1135. PubMed ID: 33228590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated analysis identifies an immune-based prognostic signature for the mesenchymal identity in colorectal cancer.
    Zhang B; Wang L; Liu Z; Shao B; Jiang W; Shu P
    Medicine (Baltimore); 2020 Jun; 99(25):e20617. PubMed ID: 32569190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
    Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
    Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
    [No Abstract]   [Full Text] [Related]  

  • 14. A mitophagy-related gene signature associated with prognosis and immune microenvironment in colorectal cancer.
    Zhang C; Zeng C; Xiong S; Zhao Z; Wu G
    Sci Rep; 2022 Nov; 12(1):18688. PubMed ID: 36333388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer.
    Cao B; Luo L; Feng L; Ma S; Chen T; Ren Y; Zha X; Cheng S; Zhang K; Chen C
    BMC Cancer; 2017 Dec; 17(1):844. PubMed ID: 29237416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prognostic index based on an eleven gene signature to predict systemic recurrences in colorectal cancer.
    Kim SK; Kim SY; Kim CW; Roh SA; Ha YJ; Lee JL; Heo H; Cho DH; Lee JS; Kim YS; Kim JC
    Exp Mol Med; 2019 Oct; 51(10):1-12. PubMed ID: 31578316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
    Dienstmann R; Villacampa G; Sveen A; Mason MJ; Niedzwiecki D; Nesbakken A; Moreno V; Warren RS; Lothe RA; Guinney J
    Ann Oncol; 2019 Oct; 30(10):1622-1629. PubMed ID: 31504112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-related gene signature in predicting prognosis of early-stage colorectal cancer patients.
    Ke J; Liu XH; Jiang XF; He Z; Xiao J; Zheng B; Chen YF; Cai ZR; Zheng XB; Zou YF; Lan P; Wu XJ; Gao F
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e62-e70. PubMed ID: 32863096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of EMT-related high-risk stage II colorectal cancer and characterisation of metastasis-related genes.
    Wang K; Song K; Ma Z; Yao Y; Liu C; Yang J; Xiao H; Zhang J; Zhang Y; Zhao W
    Br J Cancer; 2020 Aug; 123(3):410-417. PubMed ID: 32435058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.